CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

Advanced Non-Hematologic Malignancies Clinical Trial

Official title:
A Phase 1b Dose Escalation, Open-label Study Of CP-751,871 In Combination With Docetaxel In Advanced Non-hematologic Malignancies

Status Completed

Clinical Trial Summary

This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic malignancies for whom docetaxel is a reasonable treatment option.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Non-Hematologic Malignancies
Neoplasms

Clinical Trial Details

NCT number	NCT01653158
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	March 2005
Completion date	February 2009

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00915278` - A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors	Phase 1
Completed	`NCT00830869` - A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies	Phase 1
Completed	`NCT00948467` - Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies	Phase 1